We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Pulls Biosimilar Analytics Guidance Amid Comments on Flexibility
FDA Pulls Biosimilar Analytics Guidance Amid Comments on Flexibility
The FDA withdrew its draft guidance on analytical studies of biosimilars Thursday and said it plans to issue an amended version that will give sponsors “appropriate flexibility.”